Aprea Therapeutics (APRE) Misses Q4 EPS by 49c

Aprea Therapeutics (NASDAQ: APRE) reported Q4 EPS of ($0.49). Revenue for the quarter came in at $210 thousand.

For earnings history and earnings-related data on Aprea Therapeutics (APRE) click here.

You May Also Be Interested In

• Wolfe upgrades AT&T to Outperform as improving fundamentals outweigh Starlink risk
• Heritage Financial (HFWA) Tops Q2 EPS by 12c
• SpaceX short sellers gain $15.5 billion as shares fall below IPO price